Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1986
Uptake of N-[1 (S)-carboxy-(4-OH-3-125I-phenyl)ethyl]-L-Ala-L-Pro, an inhibitor of angiotensin-converting enzyme by rabbit lungs in situM Turrin, B R Pitt, J W Ryan, et al.
Circulation|July 1, 1983
Left ventricular ejection fraction during cardiac surgery: a two-dimensional echocardiographic studyJ M Dubroff, M B Clark, C Y Wong, et al.
Brain Research Bulletin|January 1, 1995
Brain spectrin: of mice and menS R Goodman, W E Zimmer, M B Clark, et al.
The International Journal of Biological Markers|October 1, 1994
Correlation between lipid-associated sialic acid and tumor burden in melanomaA C Buzaid, A B Sandler, C L Hayden, et al.
American Journal of Clinical Oncology|October 1, 1994
Neuron-specific enolase as a tumor marker in metastatic melanomaA C Buzaid, A B Sandler, C L Hayden, et al.
The New England Journal of Medicine|October 23, 1975
Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin DS W Kooh, D Fraser, H F DeLuca, et al.
Brain Research|November 14, 1994
Brain alpha erythroid spectrin: identification, compartmentalization, and beta spectrin associationsM B Clark, Y Ma, M L Bloom, et al.
Chronobiology International|January 1, 1988
Effect of changing the light/dark schedule, the time of onset of the light or dark period, or the daylength, on rhythms of epidermal cell proliferationM L Wright, Y M Myers, S T Karpells, et al.
Clinical Endocrinology|March 1, 1980
Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patientsD M Slovik, R M Neer, J L Ohman, et al.
The Journal of Clinical Endocrinology and Metabolism|March 1, 1977
The metabolism of [6-3H]1alpha, hydroxycholecalciferol to [6-3H]1alpha,25-dihydroxycholecalciferol in a patient with renal insufficiencyM F Holick, M C de Blanco, M B Clark, et al.
Pageof 4